{"entity":{"id":"nct06130553","kind":"trial","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","aka":["PRIMROSE"],"tldr":"A phase 1/2 trial of AZD3470 and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.","summary":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2026-08-27: recruiting. Enrollment is planned at 334 participants. Primary completion is estimated at 2028-12-04. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: AZD3470, Datopotamab deruxtecan. Registered primary measures: All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents; Module 1: Incidence of dose-limiting toxicities (DLT); Module 2: Progression Free Survival assessed by the Investigator according to RECIST v1.1.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06130553","url":"https://clinicaltrials.gov/study/NCT06130553"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["azd3470","datopotamab-deruxtecan"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-08-27: recruiting. Enrollment is planned at 334 participants. Primary completion is estimated at 2028-12-04. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06130553","phase":"1/2","setting":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","sponsor":"AstraZeneca","participation":[{"nct":"NCT06130553","source":"https://clinicaltrials.gov/study/NCT06130553","fetchedAt":"2026-10-07T16:54:14.819Z","studySha256":"b9db21bd75668dded1f38edb5d8f52e7294df8936aa5c4dab71ae164b5b06412","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-27","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":334,"enrolmentType":"ESTIMATED","siteCount":21,"recruitingSiteCount":18,"countries":["Australia","China","France","Japan","Netherlands","South Korea","Spain","United States"]}],"started":"2024-01-18","startedType":"actual","enrolled":334,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06130553/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"azd3470","kind":"drug","name":"AZD3470","route":"/drugs/azd3470/"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}